KR100722344B1 - 환형 단백질 티로신 키나제 억제제 - Google Patents
환형 단백질 티로신 키나제 억제제 Download PDFInfo
- Publication number
- KR100722344B1 KR100722344B1 KR1020077002337A KR20077002337A KR100722344B1 KR 100722344 B1 KR100722344 B1 KR 100722344B1 KR 1020077002337 A KR1020077002337 A KR 1020077002337A KR 20077002337 A KR20077002337 A KR 20077002337A KR 100722344 B1 KR100722344 B1 KR 100722344B1
- Authority
- KR
- South Korea
- Prior art keywords
- amino
- chloro
- thiazolecarboxamide
- methylphenyl
- methyl
- Prior art date
Links
- 0 CC(*)(CC1)CC(C)(*C(*)(*)N(*)*)CCCC1(C)N(C)C(C(*)=C)=* Chemical compound CC(*)(CC1)CC(C)(*C(*)(*)N(*)*)CCCC1(C)N(C)C(C(*)=C)=* 0.000 description 7
- KXCGRUUSNCHOGO-UHFFFAOYSA-N CC1C=C(C)C(NC(c2ccc(N)nc2)=O)=C(C)C1 Chemical compound CC1C=C(C)C(NC(c2ccc(N)nc2)=O)=C(C)C1 KXCGRUUSNCHOGO-UHFFFAOYSA-N 0.000 description 1
- PYHMJSYSGGAGSO-UHFFFAOYSA-N Cc(cccc1)c1N(Cc(cc1)ccc1OC)C(c([s]1)cnc1Cl)=O Chemical compound Cc(cccc1)c1N(Cc(cc1)ccc1OC)C(c([s]1)cnc1Cl)=O PYHMJSYSGGAGSO-UHFFFAOYSA-N 0.000 description 1
- UHNVQLADJPWIJK-UHFFFAOYSA-N Cc(cccc1)c1NC(c1cnc(N(C)c2nc(C)nc(C)c2)[s]1)=O Chemical compound Cc(cccc1)c1NC(c1cnc(N(C)c2nc(C)nc(C)c2)[s]1)=O UHNVQLADJPWIJK-UHFFFAOYSA-N 0.000 description 1
- NUZXRLLQRJHLCA-UHFFFAOYSA-N Cc(cccc1Cl)c1N(Cc(cc1)ccc1OC)C(c1cnc(Nc2nc3ccccc3cc2)[s]1)=O Chemical compound Cc(cccc1Cl)c1N(Cc(cc1)ccc1OC)C(c1cnc(Nc2nc3ccccc3cc2)[s]1)=O NUZXRLLQRJHLCA-UHFFFAOYSA-N 0.000 description 1
- WQYLFRWHITYOSB-UHFFFAOYSA-N Cc(cccc1Cl)c1NC(c1cnc(NC2CCCCC2)[s]1)=O Chemical compound Cc(cccc1Cl)c1NC(c1cnc(NC2CCCCC2)[s]1)=O WQYLFRWHITYOSB-UHFFFAOYSA-N 0.000 description 1
- FUROKDSUUHARFA-UHFFFAOYSA-N Cc(cccc1Cl)c1NC(c1cnc(Nc2nc(cccc3)c3cc2)[s]1)=O Chemical compound Cc(cccc1Cl)c1NC(c1cnc(Nc2nc(cccc3)c3cc2)[s]1)=O FUROKDSUUHARFA-UHFFFAOYSA-N 0.000 description 1
- PEUHZDTZRDAPKM-UHFFFAOYSA-N Cc1c(C(Nc2c(C)cccc2Cl)=O)[s]c(Nc2nc(C)nc(NCCN3CCOCC3)c2)n1 Chemical compound Cc1c(C(Nc2c(C)cccc2Cl)=O)[s]c(Nc2nc(C)nc(NCCN3CCOCC3)c2)n1 PEUHZDTZRDAPKM-UHFFFAOYSA-N 0.000 description 1
- HANAPVFSZINIRW-UHFFFAOYSA-N Cc1cc(Nc2ncc(C(N(Cc(cc3)ccc3OC)c3cc(OC)cc(OC)c3)=O)[s]2)nc(C)n1 Chemical compound Cc1cc(Nc2ncc(C(N(Cc(cc3)ccc3OC)c3cc(OC)cc(OC)c3)=O)[s]2)nc(C)n1 HANAPVFSZINIRW-UHFFFAOYSA-N 0.000 description 1
- OHQRMTXYUDCGFH-UHFFFAOYSA-N Cc1cccc(Cl)c1N(Cc(cc1)ccc1OC)C(c1cnc(Nc2cccc(Br)n2)[s]1)=O Chemical compound Cc1cccc(Cl)c1N(Cc(cc1)ccc1OC)C(c1cnc(Nc2cccc(Br)n2)[s]1)=O OHQRMTXYUDCGFH-UHFFFAOYSA-N 0.000 description 1
- CIZUWQHVBJNTGL-UHFFFAOYSA-N Cc1cccc(Cl)c1N(Cc(cc1)ccc1OC)C(c1cnc(Nc2ncnc(COC)c2)[s]1)=O Chemical compound Cc1cccc(Cl)c1N(Cc(cc1)ccc1OC)C(c1cnc(Nc2ncnc(COC)c2)[s]1)=O CIZUWQHVBJNTGL-UHFFFAOYSA-N 0.000 description 1
- VKUYXYNBXADBCL-UHFFFAOYSA-N Cc1cccc(Cl)c1NC(c1cnc(Nc2cc(Nc(cc3)ncc3-[n]3cncc3)ccc2)[s]1)=O Chemical compound Cc1cccc(Cl)c1NC(c1cnc(Nc2cc(Nc(cc3)ncc3-[n]3cncc3)ccc2)[s]1)=O VKUYXYNBXADBCL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Abstract
Description
Claims (7)
- 하기 화학식 I의 화합물 또는 그의 염.<화학식 I>상기 식에서,Q는 R1기로 임의로 치환된 티아졸이고;Z는 단일 결합이고;X1 및 X2는 함께 =0를 형성하고;R1은(1) 수소 또는 R6 (여기서, R6은 C1-C12알킬, C2-C10알케닐, C2-C10알키닐, C3-C12시클로알킬, C3-C12시클로알킬C1-C12알킬, C3-C12시클로알케닐, C3-C12시클로알케닐C1-C12알킬, C6-C14아릴, C6-C14아르C1-C12알킬, 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C3-C12헤테로시클로 또는 C3-C12헤테로시클로C1-C12알킬이며, 이들 각각은 비치환되거나 또는 Z1, Z2 및 1개 이상의 Z3기로 치환 됨),(2) -OH 또는 -OR6,(3) -SH 또는 -SR6,(4) -C(O)2H, -C(O)qR6, 또는 -O-C(O)qR6 (여기서, q는 1 또는 2임),(5) -SO3H 또는 -S(O)qR6,(6) 할로,(7) 시아노,(8) 니트로,(9) -Z4-NR7R8,(10) -Z4-N(R9)-Z5-NR10R11,(11) -Z4-N(R12)-Z5-R6,(12) -P(O)(OR6)2이고;R2는 수소, R6, -Z4-R6, 또는 -Z13-NR7R8이고;R3은 -Z4-R6이고, 여기서 Z4는 단일 결합이고, R6은 1개 이상의 Z3기로 치환되고 Z1 및 Z2로 임의로 치환된 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C6-C14헤테로아릴이고;R4 및 R5는(1) 각각 독립적으로 수소 또는 R6,(2) -Z4-N(R9)-Z5-NR10R11,(3) -N(R9)Z4R6이거나, 또는(4) 그들이 결합된 질소 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 3- 내지 8-원 포화 또는 불포화 헤테로시클릭 고리를 완성하고 (이 헤테로시클릭 고리에는 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 벤젠 고리가 임의로 융합될 수 있음);R7, R8, R9, R10, R11 및 R12는(1) 각각 독립적으로 수소 또는 R6이거나,(2) R7 및 R8은 함께 그들이 결합된 질소 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌, 알케닐렌 또는 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 헤테로알킬일 수 있거나, 또는(3) R9, R10 및 R11 중 임의의 두 기는 함께 그들이 결합된 질소 원자와 합쳐 서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌 또는 알케닐렌일 수 있고;R13은(1) 시아노,(2) 니트로,(3) -NH2,(4) -NHO-C1-C12알킬,(5) -OH,(6) -NHO-C6-C14아릴,(7) -NHCOO-C1-C12알킬,(8) -NHCOO-C6-C14아릴,(9) -NHSO2-C1-C12알킬,(10) -NHSO2-C6-C14아릴,(11) C6-C14아릴,(12) 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C6-C14헤테로아릴,(13) -O-C1-C12알킬, 또는(14) -O-C6-C14아릴이고;R14는(1) -NO2,(2) -COO-C1-C12알킬, 또는(3) -COO-C6-C14아릴이고,R15는(1) 수소,(2) C1-C12알킬,(3) C6-C14아릴;(4) C6-C14아릴C1-C12알킬, 또는(5) C3-C12시클로알킬이고,Z1, Z2 및 Z3은 각각 독립적으로(1) Z6 (여기서, Z6은 (i) C1-C12알킬, C2-C10알케닐, C2-C10알키닐, C3-C12시클로알킬, C3-C12시클로알킬C1-C12알킬, C3-C12시클로알케닐, C3-C12시클로알케닐C1-C12알킬, C6-C14아릴, C6-C14아르C1-C12알킬, C1-C12알킬C6-C14아릴, C3-C12시클로알킬C6-C14아 릴, 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C3-C12헤테로시클로 또는 C3-C12헤테로시클로C1-C12알킬; (ii) 1개 이상의 동일 또는 상이한 (i)기로 치환된 (i)기; 또는 (iii) Z1, Z2 및 Z3의 정의 중에서 하기 (2) 내지 (16)의 기 중 1개 이상으로 치환된 (i)기 또는 (ii)기임),(2) -OH 또는 -OZ6,(3) -SH 또는 -SZ6,(4) -C(O)qH, -C(O)qZ6 또는 -O-C(O)qZ6,(5) -SO3H, -S(O)qZ6 또는 S(O)qN(Z9)Z6,(6) 할로,(7) 시아노,(8) 니트로,(9) -Z4-NZ7Z8,(10) -Z4-N(Z9)-Z5-NZ7Z8,(11) -Z4-N(Z10)-Z5-Z6,(12) -Z4-N(Z10)-Z5-H,(13) 옥소,(14) -O-C(O)-Z6이거나,(15) Z1, Z2 및 Z3 중 임의의 두 기는 함께 그들이 결합된 원자와 합쳐서 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌 또는 알케닐렌일 수 있거나, 또는(16) Z1, Z2 및 Z3 중 임의의 두 기는 함께 그들이 결합된 원자와 합쳐서 4- 내지 8-원 고리를 완성하는 -O-(CH2)r-O- (여기서, r은 1 내지 5임)일 수 있고;Z4 및 Z5는 각각 독립적으로(1) 단일 결합,(2) -Z11-S(O)q-Z12-,(3) -Z11-C(O)-Z12-,(4) -Z11-C(S)-Z12-,(5) -Z11-O-Z12-,(6) -Z11-S-Z12-,(7) -Z11-O-C(O)-Z12-, 또는(8) -Z11-C(O)-O-Z12이고;Z7, Z8, Z9 및 Z10은(1) 각각 독립적으로 수소 또는 Z6이거나,(2) Z7 및 Z8, 또는 Z6 및 Z10은 함께 그들이 결합된 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌 또는 알케닐렌일 수 있거나, 또는(3) Z7 또는 Z8은 Z9와 함께 그들이 결합된 질소 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌 또는 알케닐렌일 수 있고,Z11 및 Z12는 각각 독립적으로(1) 단일 결합,(2) C1-C12알킬렌,(3) C2-C10알케닐렌, 또는(4) C2-C10알키닐렌이고;Z13은(1) 단일 결합,(2) -Z11-S(O)q-Z12-,(3) -Z11-C(O)-Z12-,(4) -Z11-C(S)-Z12-,(5) -Z11-O-Z12-,(6) -Z11-S-Z12-,(7) -Z11-O-C(O)-Z12-,(8) -Z11-C(O)-O-Z12-,(9) -C(NR13)-,(10) -C(CHR14)-, 또는(11) -C(C(R14)2)-이되;단, 상기 화합물 중에서 하기 화학식 vii의 화합물은 제외한다.<화학식 vii>[상기 식에서,R3e는 할로겐 또는 알킬로 임의로 치환된 피리딜 또는 피리미디닐이고,R50 및 R51은 각각 독립적으로 수소, 할로겐 또는 C1-C12알킬이고,R52 및 R53은 각각 독립적으로 수소, 할로겐, C1-C12알킬 또는 할로C1-C12알킬이고,R54 및 R56은 각각 독립적으로 수소, 할로겐, C1-C12알킬, 니트로 또는 아미노이고,R55는 수소, 할로겐, C1-C12알킬, 할로C1-C12알킬, C1-C12알콕시, 할로C1-C12알콕시, C1-C12알킬티오, 할로C1-C12알킬티오 또는 C1-C12알콕시카르보닐이고,n은 0 또는 1임]
- 제1항에 있어서, R6이 1개 이상의 Z3기로 치환된 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C6-C14헤테로아릴이고, 이때 Z3은 -Z4-NZ7Z8이며, Z4는 결합이고, Z7은 수소 또는 C1-C12알킬이고, Z8은 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C3-C12헤테로시클로-치환된 C1-C12알킬인 화합물.
- 제1항에 있어서, R6이 1개 이상의 Z3기로 치환된 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C6-C14헤테로아릴이고, 이때 Z3이 C1-C12알킬인 화합물.
- 제3항에 있어서, R1이 수소 또는 C1-C12알킬이고, R2 및 R4가 독립적으로 수소 또는 C1-C12알킬이고, R5가 비치환되거나 또는 Z1, Z2 및 1개 이상의 Z3기로 치환된 C6-C14아릴인 화합물.
- N-(2-클로로-6-메틸페닐)-2-[(4,6-디메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(4-에틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(2,6-디메틸-4-피리미디닐)아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-(3-피리다지닐아미노)-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(4-메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;2-[(6-아미노-2-피리디닐)아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(6-프로필-2-피리디닐)아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(6-에틸-4-피리미디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-(2-피리디닐아미노)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(5-메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(4-메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(3-메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'2-[(5-브로모-3-메틸-2-피리디닐)아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'2-[(6-아미노-2-피리디닐)아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'2-[(5-브로모-2-피리디닐)아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[3-(페닐메톡시)-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(5-클로로-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-에틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-프로필-2-피리디닐)아미노]-5-티아졸카르복스아미드;'2-[(3-브로모-5-메틸-2-피리디닐)아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'2-[(2-아미노-3-피리디닐)아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'2-[(3-아미노-2-피리디닐)아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-(4-피리디닐아미노)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-(3-피리디닐아미노)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-클로로-3-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(2-클로로-3-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-메톡시-3-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(3,5-디메틸-2-피라지닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(4,6-디메틸-2-피리미디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-에틸-4-피리미디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-클로로-2-피라지닐)아미노]-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-(2-피리디닐아미노)-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-[(6-메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-[(4-메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-[(4-에틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-[(4,6-디메틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'2-[(6-아미노-2-피리디닐)아미노]-N-(2,6-디메틸페닐)-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-[(6-에틸-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-[(6-프로필-2-피리디닐)아미노]-5-티아졸카르복스아미드;'2-[(2-아미노-3-피리디닐)아미노]-N-(2,6-디메틸페닐)-5-티아졸카르복스아미드;'2-[(3-아미노-2-피리디닐)아미노]-N-(2,6-디메틸페닐)-5-티아졸카르복스아미드;'2-[(6-아미노-2-메틸-4-피리미디닐)아미노]-N-(2,6-디메틸페닐)-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-[[6-(4-모르폴리닐)-3-피리다지닐]아미노]-5-티아졸카르복스아미드;'2-[(6-클로로-3-피리다지닐)아미노]-N-(2,6-디메틸페닐)-5-티아졸카르복스아미드;'N-(2,6-디메틸페닐)-2-(3-피리다지닐아미노)-5-티아졸카르복스아미드;'2-(2-피리디닐아미노)-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(6-메틸-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(5-메틸-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(4-메틸-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(3-메틸-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(5-브로모-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(5-클로로-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;2'-[(6-메톡시-3-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(4-에틸-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(6-에틸-2-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(6-클로로-3-피리디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(2,6-디메틸-4-피리미디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(4-메틸-2-피리미디닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-(2-피라지닐아미노)-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(6-클로로-2-피라지닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'2-[(3,5-디메틸-2-피라지닐)아미노]-N-(2,4,6-트리메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[[2-(4-모르폴리닐)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[[3-(4-모르폴리닐)프로필]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[메틸[3-(메틸아미노)프로필]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[[2-(테트라히드로-2-옥소-1H-이미다졸-1-일)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[(2-1H-이미다졸-4-일에틸)아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-(4-모르폴리닐)-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[(2S)-1-에틸-2-피롤리디닐]메틸]아미노]-2-메틸-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[(2R)-1-에틸-2-피롤리디닐]메틸]아미노]-2-메틸-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'2-[[6-[(2S)-2-(아미노카르보닐)-1-피롤리디닐]-2-메틸-4-피리미디닐]아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(2-히드록시에틸)아미노]-2-메틸-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[4-(히드록시메틸)-1-피페리디닐]-2-메틸-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[4-(2-히드록시에틸)-1-피페라지닐]-2-메틸-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'1-[6-[[5-[[(2-클로로-6-메틸페닐)아미노]카르보닐]-2-티아졸릴]아미노]-2-메틸-4-피리미디닐]-4-피페리딘카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[(3S)-3-메틸-1-피페라지닐]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'2-[[6-[3-(아세틸아미노)-1-피롤리디닐]-2-메틸-4-피리미디닐]아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(1-메틸-2-피롤리디닐)에틸]아미노]-2-메틸-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[[(5-메틸-2-피라지닐)메틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[2-메틸-6-[[2-(1H-1,2,3-트리아졸-1-일)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(4-모르폴리닐)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(디메틸아미노)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(테트라히드로-2-옥소-1H-이미다졸-1-일)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[메틸[2-(메틸아미노)에틸]아미노]-4-피리미디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(1-메틸-2-피롤리디닐)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(1-피롤리디닐)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[(1-에틸-2-피롤리디닐)메틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(4-피페리디닐메틸)아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'2-[[6-[[2-(아세틸아미노)에틸]아미노]-4-피리미디닐]아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(1H-1,2,3-트리아졸-1-일)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(4-모르폴리닐)-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(4-모르폴리닐)에틸]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[3-(4-모르폴리닐)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[메틸[3-(메틸아미노)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(3S)-3-메틸-1-피페라지닐]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(3-1H-이미다졸-1-일프로필)아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(2-히드록시에틸)아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(2-1H-이미다졸-1-일에틸)아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(4-모르폴리닐)-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[2-(4-모르폴리닐)에틸]아미노]-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[3-(4-모르폴리닐)프로필]아미노]-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(4-모르폴리닐)-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(3S)-3-메틸-1-피페라지닐]-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(3-히드록시-1-피롤리디닐)-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(1H-이미다졸-1-일)-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(3-히드록시-1-피롤리디닐)-3-피리다지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(1H-이미다졸-1-일)-3-피리다지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[3-(메틸아미노)-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[3-(3-히드록시-1-피롤리디닐)-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[3-(시클로프로필아미노)-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[3-(4-모르폴리닐)-2-피라지닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[3-[[2-(4-모르폴리닐)에틸]아미노]-2-피라지닐]아미노]-5-티아졸카르복스아미드;'2-[[3-[[2-(아세틸아미노)에틸]아미노]-2-피라지닐]아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(메톡시메틸)-4-피리미디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(히드록시메틸)-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-(4-모르폴리닐메틸)-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[2-(디메틸아미노)-에틸]아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[2-(4-모르폴리닐)에틸]아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[3-(4-모르폴리닐)프로필]아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[3-(2-옥소-1-피롤리디닐)프로필]아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[(2-1H-이미다졸-4-일에틸)아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[3-1H-이미다졸-1-일프로필)아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[2-(2-피리디닐)에틸]아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[[2-(3-피리디닐)에틸]아미노]메틸]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'1-[[6-[[5-[[(2-클로로-6-메틸페닐)아미노]카르보닐]-2-티아졸릴]아미노]-4-피리미디닐]메틸]-4-피페리딘카르복스아미드;'2-[[6-[[[2-(아세틸아미노)에틸]아미노]메틸]-4-피리미디닐]아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-(2-퀴놀리닐아미노)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-(3-이소퀴놀리닐아미노)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-(2-퀴녹살리닐아미노)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-4-메틸-2-[[2-메틸-6-(4-모르폴리닐)-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-4-메틸-2-[[(2-메틸-6-[[2-(4-모르폴리닐)에틸]아미노]-4-피리미디닐]아미노]-5-티아졸카르복스아미드;'2-[(2,6-디메틸-4-피리미디닐)아미노]-N-페닐-5-티아졸카르복스아미드;'2-[(2,6-디메틸-4-피리미디닐)아미노]-N-(2-메틸페닐)-5-티아졸카르복스아미드;'N-(3,5-디메톡시페닐)-2-[(2,6-디메틸-4-피리미디닐)아미노]-5-티아졸카르복스아미드;'N-[2,6-비스(1-메틸에틸)페닐]-2-[(2,6-디메틸-4-피리미디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(2,6-디메틸-4-피리미디닐)아미노]-N-메틸-5-티아졸카르복스아미드;N-,N-(2-클로로-6-메틸페닐)-(4-메톡시벤질)-2-[(6-브로모-2-피리디닐)아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(6-브로모-2-피리디닐)아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[(6-[4-(2-푸라닐카르보닐)-1-피페라지닐]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'2-[[6-[[3-(1H-벤즈이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-N-(2-클로로-6-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[4-(1H-이미다졸-1-일)부틸]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[5-(1H-이미다졸-1-일)펜틸]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[3-(4-메틸-1-피페라지닐)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[4-(1H-이미다졸-1-일)페닐]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[6-(1H-이미다졸-1-일)헥실]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[(3-1H-이미다졸-1-일프로필)아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-N-(4-메톡시페닐)-5-티아졸카르복스아미드;'2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-N-(4-페녹시페닐)-5-티아졸카르복스아미드;'N-(4-클로로페닐)-2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-N-[1-(페닐메틸)-1H-인다졸-5-일]-5-티아졸카르복스아미드;'N-(2-에틸페닐)-2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2,6-디메톡시페닐)-2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2,4-디메톡시페닐)-2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-N-페닐-5-티아졸카르복스아미드;'2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-N-(2-메틸페닐)-5-티아졸카르복스아미드;'N-(2-클로로페닐)-2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2,6-디에틸페닐)-2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-5-티아졸카르복스아미드;'N-(2-클로로-6-메틸페닐)-2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-4-메틸-5-티아졸카르복스아미드;'2-[[6-[[3-(1H-이미다졸-1-일)프로필]아미노]-2-피리디닐]아미노]-4-메틸-N-[1-(페닐메틸)-1H-인다졸-5-일]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(2-메틸-1H-벤즈이미다졸-5-일-아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[[1-[3-(1H-이미다졸-1-일)프로필]-1H-벤즈이미다졸-4-일]아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[[1-[2-(1H-이미다졸-1-일)에틸]-1H-인다졸-6-일]아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[[2-[2-(1H-이미다졸-1-일)에틸]-2H-인다졸-6-일]아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(1-메틸-1H-벤즈이미다졸-6-일)아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[(1-메틸-1H-벤즈이미다졸-5-일)아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[[2-[3-(1H-이미다졸-1-일)프로필]아미노]-1H-벤즈이미다졸-5-일]아미노]-5-티아졸카르복스아미드;N-(2-클로로-6-메틸페닐)-2-[[2-(4-모르폴리닐메틸)-1H-벤즈이미다졸-5-일]아미노]-5-티아졸카르복스아미드; 및N-(2-클로로-6-메틸페닐)-2-[[2-(1H-이미다졸-1-일메틸)-1H-벤즈이미다졸-5-일]아미노]-5-티아졸카르복스아미드로 구성된 군으로부터 선택된 화합물 또는 그의 염.
- 하기 화학식 II의 화합물 또는 그의 염.<화학식 II>상기 식에서,n은 1이고;X3은 산소이고;A는 질소이고;B는 황이고;R1은(1) 수소 또는 R6 (여기서, R6은 C1-C12알킬, C2-C10알케닐, C2-C10알키닐, C3-C12시클로알킬, C3-C12시클로알킬C1-C12알킬, C3-C12시클로알케닐, C3-C12시클로알케닐C1-C12알킬, C6-C14아릴, C6-C14아르C1-C12알킬, 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C3-C12헤테로시클로 또는 C3-C12헤테로시클로C1-C12알킬이고, 이들 각각은 비치환되거나 또는 Z1, Z2 및 1개 이상의 Z3기로 치환됨),(2) -OH 또는 -OR6,(3) -SH 또는 -SR6,(4) -C(O)2H, -C(O)qR6, 또는 -O-C(O)qR6 (여기서, q는 1 또는 2임),(5) -SO3H 또는 -S(O)qR6,(6) 할로,(7) 시아노,(8) 니트로,(9) -Z4-NR7R8,(10) -Z4-N(R9)-Z5-NR10R11,(11) -Z4-N(R12)-Z5-R6,(12) -P(O)(OR6)2이고;R2는(1) 수소 또는 R6,(2) -Z4-R6, 또는(3) -Z13-NR7R8이고;R3은 -Z4-R6이고, 여기서 Z4는 결합이고, R6은 1개 이상의 Z3기로 치환되고 Z1 및 Z2로 임의로 치환된 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C6-C14헤테로아릴이고;R4 및 R5는 각각 독립적으로(1) 수소 또는 R6,(2) -Z4-N(R9)-Z5-NR10R11,(3) -N(R9)Z4R6이거나, 또는(4) 그들이 결합된 질소 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 헤테로시클릭 고리를 완성하고 (이 헤테로시클릭 고리에는 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 벤젠 고리가 임의로 융합될 수 있음);R7, R8, R9, R10, R11 및 R12는(1) 각각 독립적으로 수소 또는 R6이거나,(2) R7 및 R8은 함께 그들이 결합된 질소 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌, 알케닐렌 또는 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 헤테로알킬일 수 있거나, 또는(3) R9, R10 및 R11 중 임의의 두 기는 함께 그들이 결합된 질소 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌 또는 알케닐렌일 수 있고;R13은(1) 시아노,(2) 니트로,(3) -NH2,(4) -NHO-C1-C12알킬,(5) -OH,(6) -NHO-C6-C14아릴,(7) -NHCOO-C1-C12알킬,(8) -NHCOO-C6-C14아릴,(9) -NHSO2-C1-C12알킬,(10) -NHSO2-C6-C14아릴,(11) C6-C14아릴,(12) 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C6-C14헤테로아릴,(13) -O-C1-C12알킬, 또는(14) -O-C6-C14아릴이고;R14는(1) -NO2,(2) -COO-C1-C12알킬, 또는(3) -COO-C6-C14아릴이고,R15는(1) 수소,(2) C1-C12알킬,(3) C6-C14아릴;(4) C6-C14아릴C1-C12알킬, 또는(5) C3-C12시클로알킬이고,Z1, Z2 및 Z3은 각각 독립적으로(1) 수소 또는 Z6 (여기서, Z6은 (i) C1-C12알킬, C2-C10알케닐, C2-C10알키닐, C3-C12시클로알킬, C3-C12시클로알킬C1-C12알킬, C3-C12시클로알케닐, C3-C12시클로알케닐C1-C12알킬, C6-C14아릴, C6-C14아르C1-C12알킬, C1-C12알킬C6-C14아릴, C3-C12시클로알킬C6-C14아릴, 질소 원자, 산소 원자 및 황 원자 중에서 선택된 1개 이상의 헤테로원자를 갖는 C3-C12헤테로시클로 또는 C3-C12헤테로시클로C1-C12알킬; (ii) 1개 이상의 동일 또는 상이한 (i)기로 치환된 (i)기; 또는 (iii) Z1, Z2 및 Z3의 정의 중에서 하기 (2) 내지 (16)의 기 중 1개 이상으로 치환된 (i)기 또는 (ii)기임),(2) -OH 또는 -OZ6,(3) -SH 또는 -SZ6,(4) -C(O)qH, -C(O)qZ6 또는 -O-C(O)qZ6,(5) -SO3H, -S(O)qZ6 또는 S(O)qN(Z9)Z6,(6) 할로,(7) 시아노,(8) 니트로,(9) -Z4-NZ7Z8,(10) -Z4-N(Z9)-Z5-NZ7Z8,(11) -Z4-N(Z10)-Z5-Z6,(12) -Z4-N(Z10)-Z5-H,(13) 옥소,(14) -O-C(O)-Z6이거나,(15) Z1, Z2 및 Z3 중 임의의 두 기는 함께 그들이 결합된 원자와 합쳐서 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌 또는 알케닐렌일 수 있거나, 또는(16) Z1, Z2 및 Z3 중 임의의 두 기는 함께 그들이 결합된 원자와 합쳐서 4- 내지 8-원 고리를 완성하는 -O-(CH2)r-O- (여기서, r은 1 내지 5임)일 수 있고;Z4 및 Z5는 각각 독립적으로(1) 단일 결합,(2) -Z11-S(O)q-Z12-,(3) -Z11-C(O)-Z12-,(4) -Z11-C(S)-Z12-,(5) -Z11-O-Z12-,(6) -Z11-S-Z12-,(7) -Z11-O-C(O)-Z12-, 또는(8) -Z11-C(O)-O-Z12이고;Z7, Z8, Z9 및 Z10은(1) 각각 독립적으로 수소 또는 Z6이거나,(2) Z7 및 Z8, 또는 Z6 및 Z10은 함께 그들이 결합된 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알킬렌 또는 알케닐렌일 수 있거나, 또는(3) Z7 또는 Z8은 Z9와 함께 그들이 결합된 질소 원자와 합쳐서 비치환되거나 또는 Z1, Z2 및 Z3으로 치환된 3- 내지 8-원 포화 또는 불포화 고리를 완성하는 알 킬렌 또는 알케닐렌일 수 있고,Z11 및 Z12는 각각 독립적으로(1) 단일 결합,(2) C1-C12알킬렌,(3) C2-C10알케닐렌, 또는(4) C2-C10알키닐렌이고;Z13은(1) 단일 결합,(2) -Z11-S(O)q-Z12-,(3) -Z11-C(O)-Z12-,(4) -Z11-C(S)-Z12-,(5) -Z11-O-Z12-,(6) -Z11-S-Z12-,(7) -Z11-O-C(O)-Z12-,(8) -Z11-C(O)-O-Z12-,(9) -C(NR13)-,(10) -C(CHR14)-, 또는(11) -C(C(R14)2)-이되;단, 상기 화합물 중에서 하기 화학식 vii의 화합물은 제외한다.<화학식 vii>[상기 식에서,R3e는 할로겐 또는 C1-C12알킬로 임의로 치환된 피리딜 또는 피리미디닐이고,R50 및 R51은 각각 독립적으로 수소, 할로겐 또는 C1-C12알킬이고,R52 및 R53은 각각 독립적으로 수소, 할로겐, C1-C12알킬 또는 할로C1-C12알킬이고,R54 및 R56은 각각 독립적으로 수소, 할로겐, C1-C12알킬, 니트로 또는 아미노이고,R55는 수소, 할로겐, C1-C12알킬, 할로C1-C12알킬, C1-C12알콕시, 할로C1-C12알콕시, C1-C12알킬티오, 할로C1-C12알킬티오 또는 C1-C12알콕시카르보닐이고,n은 0 또는 1임]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12951099P | 1999-04-15 | 1999-04-15 | |
US60/129,510 | 1999-04-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017013067A Division KR100710100B1 (ko) | 1999-04-15 | 2000-04-12 | 환형 단백질 티로신 키나제 억제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070020153A KR20070020153A (ko) | 2007-02-16 |
KR100722344B1 true KR100722344B1 (ko) | 2007-05-29 |
Family
ID=22440334
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077002337A KR100722344B1 (ko) | 1999-04-15 | 2000-04-12 | 환형 단백질 티로신 키나제 억제제 |
KR1020017013067A KR100710100B1 (ko) | 1999-04-15 | 2000-04-12 | 환형 단백질 티로신 키나제 억제제 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020017013067A KR100710100B1 (ko) | 1999-04-15 | 2000-04-12 | 환형 단백질 티로신 키나제 억제제 |
Country Status (27)
Country | Link |
---|---|
US (12) | US6596746B1 (ko) |
EP (3) | EP1169038B9 (ko) |
JP (1) | JP3989175B2 (ko) |
KR (2) | KR100722344B1 (ko) |
CN (2) | CN1348370A (ko) |
AU (1) | AU779089B2 (ko) |
BR (2) | BRPI0009721B1 (ko) |
CA (1) | CA2366932C (ko) |
CY (2) | CY1113312T1 (ko) |
CZ (1) | CZ302788B6 (ko) |
DK (1) | DK1169038T3 (ko) |
ES (1) | ES2391550T3 (ko) |
FR (1) | FR13C0003I2 (ko) |
HK (2) | HK1042433B (ko) |
HU (1) | HUP0202708A3 (ko) |
ID (1) | ID30460A (ko) |
IL (2) | IL144910A0 (ko) |
LU (1) | LU92146I2 (ko) |
MX (1) | MXPA01010292A (ko) |
NO (3) | NO322470B1 (ko) |
NZ (1) | NZ513639A (ko) |
PL (1) | PL215901B1 (ko) |
PT (1) | PT1169038E (ko) |
RU (2) | RU2260592C9 (ko) |
TR (1) | TR200102969T2 (ko) |
WO (1) | WO2000062778A1 (ko) |
ZA (1) | ZA200107204B (ko) |
Families Citing this family (290)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2273083C (en) * | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US20020058286A1 (en) * | 1999-02-24 | 2002-05-16 | Danishefsky Samuel J. | Synthesis of epothilones, intermediates thereto and analogues thereof |
US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
BRPI0009721B1 (pt) * | 1999-04-15 | 2018-11-21 | Bristol-Myers Squibb Holdings Ireland | inibidores de tirosina quinase de proteína cíclica |
US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
ATE309241T1 (de) | 1999-09-10 | 2005-11-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
GB0001930D0 (en) * | 2000-01-27 | 2000-03-22 | Novartis Ag | Organic compounds |
JP2003520854A (ja) | 2000-01-27 | 2003-07-08 | サイトビア インコーポレイテッド | カスパーゼのアクチベーターおよびアポトーシスのインデューサーとしての置換ニコチンアミドおよび類似物およびそれらの使用 |
US7427689B2 (en) * | 2000-07-28 | 2008-09-23 | Georgetown University | ErbB-2 selective small molecule kinase inhibitors |
EP1320365A4 (en) * | 2000-09-21 | 2004-03-17 | Bristol Myers Squibb Co | SUBSTITUTED AZOLE DERIVATIVES AS AN INHIBITOR OF THE CORTICOTROPIN RELEASE FACTOR |
US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
AU2002231139B2 (en) | 2000-12-21 | 2007-03-22 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
EP1671969A3 (en) * | 2000-12-21 | 2006-07-26 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
FR2820136A1 (fr) * | 2001-01-26 | 2002-08-02 | Aventis Pharma Sa | Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation |
WO2002102313A2 (en) * | 2001-06-19 | 2002-12-27 | Bristol-Myers Squibb Company | Pyrimidine inhibitors of phosphodiesterase (pde) 7 |
ES2255621T3 (es) | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
AUPR688101A0 (en) * | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
CA2810339A1 (en) | 2001-08-10 | 2003-02-20 | Novartis Ag | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
US7638522B2 (en) | 2001-08-13 | 2009-12-29 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile |
US8101629B2 (en) | 2001-08-13 | 2012-01-24 | Janssen Pharmaceutica N.V. | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7265134B2 (en) * | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
US6677487B2 (en) | 2001-08-30 | 2004-01-13 | Pharmacia Corporation | α-haloenamine reagents |
US6825184B2 (en) | 2001-10-18 | 2004-11-30 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-Disubstituted benzo-fused urea compounds |
PL368917A1 (en) | 2001-11-01 | 2005-04-04 | Janssen Pharmaceutica N.V. | Amide derivatives as glycogen synthase kinase 3-beta inhibitors |
BR0213792A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3) |
US6693097B2 (en) | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
MXPA04005181A (es) | 2001-11-30 | 2005-06-17 | Synta Pharmaceuticals Corp | Compuestos de pirimidina. |
US8299108B2 (en) | 2002-03-29 | 2012-10-30 | Novartis Ag | Substituted benzazoles and methods of their use as inhibitors of raf kinase |
AU2003226211B2 (en) | 2002-03-29 | 2008-05-29 | Novartis Vaccines And Diagnostics, Inc. | Substituted benzazoles and use thereof as RAF kinase inhibitors |
AUPS251402A0 (en) * | 2002-05-23 | 2002-06-13 | Cytopia Pty Ltd | Kinase inhibitors |
KR101169964B1 (ko) | 2002-05-23 | 2012-08-06 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 키나아제 저해제 |
CA2486187C (en) * | 2002-05-23 | 2013-02-19 | Cytopia Pty Ltd. | Kinase inhibitors |
AU2003248549B2 (en) | 2002-05-24 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
WO2004012746A2 (en) * | 2002-08-02 | 2004-02-12 | The Regents Of The University Of California | New uses for inhibitors of inosine monophosphate dehydrogenase |
NZ538611A (en) | 2002-08-09 | 2007-03-30 | Janssen Pharmaceutica Nv | Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
WO2004014904A1 (en) * | 2002-08-09 | 2004-02-19 | Pfizer Inc. | Antiproliferative 2-(heteroaryl)-aminothiazole compounds, pharmaceutical compositions and methods for their use |
DK1767535T3 (da) * | 2002-08-23 | 2010-04-12 | Sloan Kettering Inst Cancer | Syntese af epothiloner, mellemprodukter deraf, analoge og deres anvendelse |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2004020583A2 (en) | 2002-08-27 | 2004-03-11 | Bristol-Myers Squibb Company | Polynucleotide predictor set for identifying protein tyrosine kinase modulators |
US7537891B2 (en) | 2002-08-27 | 2009-05-26 | Bristol-Myers Squibb Company | Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells |
AU2003285007A1 (en) * | 2002-10-30 | 2004-06-07 | Merck & Co., Inc. | Kinase inhibitors |
US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
CN100360526C (zh) | 2002-11-18 | 2008-01-09 | 坎莫森特里克斯公司 | 芳基磺酰胺 |
US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
US7169771B2 (en) | 2003-02-06 | 2007-01-30 | Bristol-Myers Squibb Company | Thiazolyl-based compounds useful as kinase inhibitors |
CL2004000192A1 (es) | 2003-02-07 | 2005-03-18 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. |
PL379553A1 (pl) * | 2003-02-10 | 2006-10-16 | Amgen Inc. | Ligandy receptora waniloidowego oraz ich zastosowanie w leczeniu |
CL2004000306A1 (es) | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
US7427683B2 (en) | 2003-04-25 | 2008-09-23 | Ortho-Mcneil Pharmaceutical, Inc. | c-fms kinase inhibitors |
US7790724B2 (en) | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
EP1631560A2 (en) * | 2003-04-25 | 2006-03-08 | 3-Dimensional Pharmaceuticals, Inc. | C-fms kinase inhibitors |
US20050113566A1 (en) * | 2003-04-25 | 2005-05-26 | Player Mark R. | Inhibitors of C-FMS kinase |
PL1635824T3 (pl) | 2003-06-03 | 2010-01-29 | Novartis Ag | 5-Członowe heterocykliczne inhibitory P-38 |
DK2298743T3 (da) | 2003-06-26 | 2012-11-26 | Novartis Ag | p38-Kinaseinhibitorer på grundlag af en 5-leddet heterocyclisk ring |
TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
US20050009891A1 (en) * | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
CA2531232A1 (en) | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
PL1651612T3 (pl) | 2003-07-22 | 2012-09-28 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
JP2007506763A (ja) * | 2003-09-24 | 2007-03-22 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なイミダゾール組成物 |
JP4795022B2 (ja) | 2003-09-30 | 2011-10-19 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヘテロ環化合物を含有する新規な抗真菌剤 |
DE602004021838D1 (de) | 2003-10-16 | 2009-08-13 | Novartis Vaccines & Diagnostic | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer |
CA2545259A1 (en) | 2003-11-10 | 2005-05-26 | Synta Pharmaceuticals, Corp. | Heteroaryl-hydrazone compounds |
US7338951B2 (en) | 2003-11-10 | 2008-03-04 | Synta Pharmaceuticals Corp. | Pyridine compounds |
EP1687002A4 (en) | 2003-11-10 | 2008-07-23 | Synta Pharmaceuticals Corp | CONDENSED HETEROCYCLIC COMPOUNDS |
ES2578254T3 (es) * | 2003-12-03 | 2016-07-22 | Ym Biosciences Australia Pty Ltd | Inhibidores de cinasas basados en azol |
CN1878767B (zh) * | 2003-12-03 | 2010-05-05 | 西托匹亚研究有限公司 | 唑基激酶抑制剂 |
EP2233174B1 (en) * | 2004-01-21 | 2016-07-20 | Emory University | Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection |
ES2791303T3 (es) * | 2004-01-30 | 2020-11-03 | Vertex Pharma | Compuesto intermedio de moduladores de transportadores de casete de unión a ATP |
BRPI0507271A (pt) * | 2004-01-30 | 2007-06-26 | Ab Science | 2-(3-substituìda-aril)amino-4-aril-tiazóis como inibidores de tirosina cinase |
US20050215795A1 (en) * | 2004-02-06 | 2005-09-29 | Bang-Chi Chen | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
TWI338004B (en) * | 2004-02-06 | 2011-03-01 | Bristol Myers Squibb Co | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
CN1980909B (zh) * | 2004-02-06 | 2010-08-25 | 布里斯托尔-迈尔斯·斯奎布公司 | 作为激酶抑制剂的2-氨基噻唑-5-芳香族甲酰胺的制备方法 |
WO2005077938A1 (en) * | 2004-02-11 | 2005-08-25 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
US7384968B2 (en) * | 2004-04-01 | 2008-06-10 | Pfizer Inc. | Thiazole-amine compounds for the treatment of neurodegenerative disorders |
WO2005103022A1 (en) * | 2004-04-20 | 2005-11-03 | Transtech Pharma, Inc. | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US20110104186A1 (en) | 2004-06-24 | 2011-05-05 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
ATE485300T1 (de) * | 2004-07-16 | 2010-11-15 | Sunesis Pharmaceuticals Inc | Als aurora-kinase-inhibitoren nutzbare thienopyrimidine |
RU2007109073A (ru) | 2004-08-13 | 2008-09-20 | Дженентек, Инк. (Us) | Ингибиторы для атф-зависимого фермента на основе тиазола |
WO2006032273A1 (en) | 2004-09-22 | 2006-03-30 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
US20060069101A1 (en) * | 2004-09-27 | 2006-03-30 | Kim Kyoung S | Prodrugs of protein tyrosine kinase inhibitors |
US7662837B2 (en) * | 2004-10-22 | 2010-02-16 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
US7645755B2 (en) * | 2004-10-22 | 2010-01-12 | Janssen Pharmaceutical N.V. | Inhibitors of c-fms kinase |
TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
WO2006053109A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Heteroaryl compounds |
US7923557B2 (en) | 2004-11-10 | 2011-04-12 | Synta Pharmaceuticals Corporation | Process for preparing trisubstituted pyrimidine compounds |
AU2005304393B2 (en) | 2004-11-10 | 2012-09-27 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
SE0402762D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
SE0402763D0 (sv) * | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Nitro indazole derivatives |
CA2587590A1 (en) | 2004-11-19 | 2006-06-08 | Synta Pharmaceuticals Corp. | Pyrimidine compounds and uses thereof |
KR20070094754A (ko) * | 2004-12-01 | 2007-09-21 | 데브젠 엔브이 | 이온 채널, 특히 Kv 패밀리로부터의 이온 채널과상호작용하는 5-카복사미도 치환된 티아졸 유도체 |
AU2005321091B2 (en) | 2004-12-30 | 2012-04-12 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and Aurora kinases |
DE602006020327D1 (de) * | 2005-01-19 | 2011-04-07 | Bristol Myers Squibb Co | 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen |
US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
AU2006207321B2 (en) | 2005-01-21 | 2012-09-06 | Astex Therapeutics Limited | Pharmaceutical compounds |
AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
PE20061394A1 (es) * | 2005-03-15 | 2006-12-15 | Bristol Myers Squibb Co | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas |
JP4874958B2 (ja) | 2005-03-30 | 2012-02-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジン誘導体を含有する抗真菌剤 |
US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
FR2885129B1 (fr) | 2005-04-29 | 2007-06-15 | Proskelia Sas | Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation. |
SI1885339T1 (sl) * | 2005-05-05 | 2015-10-30 | Bristol-Myers Squibb Holdings Ireland | Formulacije inhibitorja src/abl |
US20060281788A1 (en) * | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor |
CA2613355C (en) | 2005-06-24 | 2014-04-22 | Duke University | A direct drug delivery system based on thermally responsive biopolymers |
WO2007002637A1 (en) * | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | N-linked heterocyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
US7816382B2 (en) | 2005-06-27 | 2010-10-19 | Bristol-Myers Squibb Company | Linear urea mimics antagonists of P2Y1 receptor useful in the treatment of thrombotic condition |
ATE485269T1 (de) * | 2005-06-27 | 2010-11-15 | Bristol Myers Squibb Co | C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden |
US7714002B2 (en) * | 2005-06-27 | 2010-05-11 | Bristol-Myers Squibb Company | Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
ES2342194T3 (es) * | 2005-08-05 | 2010-07-02 | Bristol-Myers Squibb Company | Preparacion de derivados de acido 2-amino-tiazol-5-carboxilico. |
WO2007035874A1 (en) * | 2005-09-21 | 2007-03-29 | Bristol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
US20070123539A1 (en) | 2005-10-20 | 2007-05-31 | University Of South Florida | Treatment of Restenosis and Stenosis with Dasatinib |
TWI385169B (zh) | 2005-10-31 | 2013-02-11 | Eisai R&D Man Co Ltd | 經雜環取代之吡啶衍生物及含有彼之抗真菌劑 |
RU2597364C2 (ru) * | 2005-11-01 | 2016-09-10 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназ |
ES2372540T3 (es) | 2005-11-01 | 2012-01-23 | Array Biopharma, Inc. | Activadores de glucocinasa. |
EP1948820A2 (en) * | 2005-11-04 | 2008-07-30 | Bristol-Myers Squibb Pharma Company | T315a and f317i mutations of bcr-abl kinase domain |
US8007995B2 (en) * | 2005-11-10 | 2011-08-30 | Bristol-Myers Squibb Company | Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers |
WO2007059078A1 (en) * | 2005-11-14 | 2007-05-24 | Dana-Farber Cancer Institute | Treatment of multiple myeloma with dasatinib |
US20070149523A1 (en) * | 2005-11-14 | 2007-06-28 | Jan Ehlert | Thiazole Analogues and Uses Thereof |
EP1955073A2 (en) * | 2005-11-15 | 2008-08-13 | Brystol-Myers Squibb Company | Methods of identifying and treating individuals exhibiting mdr-1 overexpression with protein tyrosine kinase inhibitors and combinations thereof |
US7705009B2 (en) * | 2005-11-22 | 2010-04-27 | Hoffman-La Roche Inc. | 4-aminopyrimidine-5-thione derivatives |
ES2335360T3 (es) | 2005-11-25 | 2010-03-25 | Galapagos Sas | Derivados de urea utiles como moduladores de los receptores de calcio. |
ATE529536T1 (de) * | 2005-12-01 | 2011-11-15 | Bristol Myers Squibb Co | Verfahren zur identifizierung und behandlung von komplexe karyotypen zeigenden individuen |
EP1976839A4 (en) * | 2006-01-26 | 2011-06-15 | Foldrx Pharmaceuticals Inc | COMPOUNDS AND METHOD FOR MODULATING A PROTEIN TRANSPORT |
EP1987028A2 (en) | 2006-02-10 | 2008-11-05 | Transtech Pharma, Inc. | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors |
US20070213378A1 (en) * | 2006-03-10 | 2007-09-13 | Lymphosign Inc. | Compounds for modulating cell proliferation, compositions and methods related thereto |
US20070219370A1 (en) * | 2006-03-15 | 2007-09-20 | Bristol-Myers Squibb Company | Process for preparing n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino] -5-thiazolecarboxamide and related metabolites thereof |
US20090306094A1 (en) * | 2006-03-17 | 2009-12-10 | Bristol-Myers Squibb Company | Methods Of Identifying And Treating Individuals Exhibiting Mutant Bcr/Abl Kinase Polypeptides |
WO2007123269A1 (ja) | 2006-04-19 | 2007-11-01 | Astellas Pharma Inc. | アゾールカルボキサミド誘導体 |
EP2016074B1 (en) | 2006-04-20 | 2016-01-13 | Janssen Pharmaceutica N.V. | Inhibitors of c-fms kinase |
US8697716B2 (en) | 2006-04-20 | 2014-04-15 | Janssen Pharmaceutica Nv | Method of inhibiting C-KIT kinase |
SI2021335T1 (sl) | 2006-04-20 | 2011-09-30 | Janssen Pharmaceutica Nv | Heterocikliäśne spojine kot zaviralci c-fms kinaze |
EP2016067B1 (en) * | 2006-04-28 | 2012-08-08 | Syngenta Participations AG | Insecticidal compounds |
WO2007138110A2 (en) * | 2006-06-01 | 2007-12-06 | Devgen N.V. | Compounds that interact with ion channels, in particular with ion channels from the kv family |
TWI391386B (zh) * | 2006-06-28 | 2013-04-01 | Glaxo Group Ltd | 化合物 |
GB0613674D0 (en) * | 2006-07-10 | 2006-08-16 | Proskelia Sas | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor |
US7888361B2 (en) * | 2006-09-11 | 2011-02-15 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
US20080221132A1 (en) * | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
AU2007299764B2 (en) | 2006-09-22 | 2011-10-13 | Novartis Ag | Method of optimizing the treatment of Philadelphia-positive leukemia with Abl tyrosine kinase inhibitors |
JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
WO2008044045A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
US7960569B2 (en) * | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
KR20090075869A (ko) | 2006-10-31 | 2009-07-09 | 쉐링 코포레이션 | 단백질 키나제 억제제로서의 2-아미노티아졸-4-카복실산 아미드 |
CA2668255A1 (en) | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
WO2008054702A1 (en) | 2006-10-31 | 2008-05-08 | Schering Corporation | Anilinopiperazine derivatives and methods of use thereof |
CA2672893C (en) | 2006-12-15 | 2016-02-23 | Abraxis Bioscience, Inc. | Triazine derivatives and their therapeutical applications |
CN101265274B (zh) * | 2007-02-16 | 2013-09-04 | 中国医学科学院药物研究所 | 嘧啶噻唑胺衍生物、及其制法和药物组合物与用途 |
TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
EP2166860B1 (en) * | 2007-06-07 | 2016-09-21 | Intra-Cellular Therapies, Inc. | Novel heterocycle compounds and uses thereof |
EP2166858A4 (en) | 2007-06-07 | 2011-08-03 | Intra Cellular Therapies Inc | NEW HETEROCYCLIC COMPOUNDS AND ITS USE |
US20100292236A1 (en) | 2007-07-19 | 2010-11-18 | H. Lundbeck A/S | 5-Membered Heterocyclic Amides And Related Compounds |
US20090076025A1 (en) * | 2007-09-14 | 2009-03-19 | Protia, Llc | Deuterium-enriched dasatinib |
EP2209778B1 (en) | 2007-09-21 | 2012-08-29 | Array Biopharma, Inc. | Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
JO3240B1 (ar) * | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
US8067423B2 (en) * | 2007-10-23 | 2011-11-29 | Teva Pharmaceutical Industries Ltd. | Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof |
CA2703106C (en) * | 2007-10-24 | 2015-12-01 | Astellas Pharma Inc. | Azolecarboxamide derivatives as trka inhibitors |
EP2062578A1 (en) | 2007-11-12 | 2009-05-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Novel use of chemical compounds for the treatment of AIDS |
US8338425B2 (en) * | 2007-12-10 | 2012-12-25 | Concert Pharmaceuticals, Inc. | Heterocyclic kinase inhibitors |
EP2235537A2 (en) * | 2008-01-25 | 2010-10-06 | Bristol-Myers Squibb Pharma Company | Identification of predictive markers of response to dasatinib in human colon cancer |
EP2260021B1 (de) * | 2008-03-27 | 2014-04-23 | Grünenthal GmbH | Substituierte 4-aminocyclohexan-derivate |
DE102008031036A1 (de) | 2008-06-30 | 2009-12-31 | Dömling, Alexander, Priv.-Doz. Dr. | Dasatinib zur Anwendung in der Organtransplantation |
CN102159247A (zh) * | 2008-07-30 | 2011-08-17 | 日东电工株式会社 | 药物载体 |
CA2731442A1 (en) * | 2008-08-29 | 2010-03-04 | Transtech Pharma, Inc. | Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use |
AR074183A1 (es) | 2008-10-29 | 2010-12-29 | Du Pont | Tratamiento de corrientes de residuos |
US20100113520A1 (en) * | 2008-11-05 | 2010-05-06 | Principia Biopharma, Inc. | Kinase knockdown via electrophilically enhanced inhibitors |
AU2009322625A1 (en) * | 2008-12-01 | 2011-07-21 | University Of Central Florida Research Foundation, Inc. | Drug composition cytotoxic for pancreatic cancer cells |
US8530492B2 (en) | 2009-04-17 | 2013-09-10 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
US8816077B2 (en) | 2009-04-17 | 2014-08-26 | Nektar Therapeutics | Oligomer-protein tyrosine kinase inhibitor conjugates |
WO2010139981A2 (en) * | 2009-06-03 | 2010-12-09 | Generics [Uk] Limited | Processes for preparing crystalline forms |
KR101457027B1 (ko) | 2009-06-09 | 2014-10-31 | 캘리포니아 캐피탈 에쿼티, 엘엘씨 | 트리아진 유도체와 이들의 치료적 용도 |
CN102573484B (zh) | 2009-06-09 | 2015-07-01 | 加利福尼亚资本权益有限责任公司 | 苄基取代的三嗪衍生物及其治疗应用 |
US10640457B2 (en) | 2009-12-10 | 2020-05-05 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
CN101812060B (zh) * | 2010-02-02 | 2011-08-17 | 南京卡文迪许生物工程技术有限公司 | 一种简捷制备高纯度达沙替尼的新方法以及中间体化合物 |
CN101845045A (zh) * | 2010-02-02 | 2010-09-29 | 南京卡文迪许生物工程技术有限公司 | 一种新的达沙替尼合成方法 |
EP2359813A1 (en) | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
CN101948467B (zh) * | 2010-05-17 | 2012-07-25 | 苏州波锐生物医药科技有限公司 | 噻唑酰胺类化合物及其在制备抗恶性肿瘤药物中的用途 |
CA2798578C (en) | 2010-05-21 | 2015-12-29 | Chemilia Ab | Novel pyrimidine derivatives |
AU2011284341A1 (en) | 2010-07-30 | 2013-02-21 | Ranbaxy Laboratories Limited | N-Methylformamide solvate of dasatinib |
WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
EP2654428B1 (en) * | 2010-12-22 | 2018-02-14 | The Trustees of Columbia University in the City of New York | Histone acetyltransferase modulators and usese thereof |
WO2012098416A1 (en) | 2011-01-21 | 2012-07-26 | Sun Pharma Advanced Research Company Ltd | Diarylacetylene hydrazide containing tyrosine kinase inhibitors |
WO2012118599A1 (en) | 2011-02-28 | 2012-09-07 | Emory University | C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication |
MX2013010330A (es) | 2011-03-09 | 2014-11-26 | Richard G Pestell | Líneas de célula cancerosa de próstata, signaturas de gen, y usos de las mismas. |
EP2688883B1 (en) | 2011-03-24 | 2016-05-18 | Noviga Research AB | Pyrimidine derivatives |
EP2717883B1 (en) | 2011-05-02 | 2017-03-22 | Stichting VUmc | Protection against endothelial barrier dysfunction through inhibition of the tyrosine kinase abl-related gene (arg) |
EP2707357B1 (en) | 2011-05-10 | 2017-01-18 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
RU2013154412A (ru) * | 2011-05-10 | 2015-06-20 | Мерк Шарп И Доум Корп. | Аминопиримидины в качестве ингибиторов syc |
CN102898424A (zh) * | 2011-07-29 | 2013-01-30 | 江苏奥赛康药业股份有限公司 | 达沙替尼新的多晶型物及其制备方法 |
WO2013065063A1 (en) | 2011-11-03 | 2013-05-10 | Cadila Healthcare Limited | Anhydrous form of dasatinib, process for its preparation and its use |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
US9145406B2 (en) | 2012-04-20 | 2015-09-29 | Shilpa Medicare Limited | Process for preparing dasatinib monohydrate |
CN104271572A (zh) * | 2012-05-11 | 2015-01-07 | 艾伯维公司 | 用作nampt抑制剂的噻唑羧酰胺衍生物 |
US9453836B2 (en) | 2012-05-14 | 2016-09-27 | Richard G. Pestell | Use of modulators of CCR5 in the treatment of cancer and cancer metastasis |
KR20150020683A (ko) * | 2012-06-15 | 2015-02-26 | 바스프 에스이 | 다사티닙 및 선택된 공-결정 형성제를 포함하는 다성분 결정 |
JP6464084B2 (ja) | 2012-07-27 | 2019-02-06 | イズミ テクノロジー,エルエルシー | 排出阻害剤およびこれを用いる治療法 |
JOP20180012A1 (ar) | 2012-08-07 | 2019-01-30 | Janssen Pharmaceutica Nv | عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد |
IN2015DN00659A (ko) | 2012-08-07 | 2015-06-26 | Janssen Pharmaceutica Nv | |
NZ704666A (en) | 2012-08-23 | 2018-05-25 | Alios Biopharma Inc | Compounds for the treatment of paramoxyvirus viral infections |
ME03455B (me) | 2012-09-10 | 2020-01-20 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
CN103788085B (zh) * | 2012-10-31 | 2016-09-07 | 复旦大学 | 2-(喹唑啉-4-氨基)-5-噻唑甲酰胺类衍生物及其生物药物用途 |
CZ306598B6 (cs) | 2012-12-06 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy a čištění nových i známých polymorfů a solvátů dasatinibu |
WO2014102759A2 (en) | 2012-12-31 | 2014-07-03 | Ranbaxy Laboratories Limited | Process for the preparation of dasatinib and its intermediates |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
CN104151321B (zh) * | 2013-05-15 | 2016-09-07 | 复旦大学 | N-(2-氯-6-甲基苯基)-2[(2-甲基嘧啶-4-基)氨基]噻唑-5-甲酰胺化合物及其制备方法和用途 |
MX363689B (es) * | 2013-05-23 | 2019-03-29 | Kalvista Pharmaceuticals Ltd | Derivados de heterociclicos. |
CN104225611B (zh) * | 2013-06-18 | 2017-06-30 | 天津键凯科技有限公司 | 达沙替尼与非线性构型聚乙二醇的结合物 |
TW201534597A (zh) * | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
WO2015011578A1 (en) * | 2013-07-22 | 2015-01-29 | Shilpa Medicare Limited | Dasatinib glucuronate salt and process for preparation thereof |
WO2015011119A2 (en) | 2013-07-25 | 2015-01-29 | Basf Se | Salts of dasatinib in amorphous form |
US9556164B2 (en) | 2013-07-25 | 2017-01-31 | Basf Se | Salts of Dasatinib in crystalline form |
TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
CN103588758A (zh) * | 2013-11-04 | 2014-02-19 | 南京大学 | 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用 |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
IN2013MU03610A (ko) | 2013-12-18 | 2015-04-24 | Dharmesh Mahendrabhai Shah | |
CZ306732B6 (cs) | 2013-12-19 | 2017-05-31 | Zentiva, K.S. | Způsob přípravy bezvodé polymorfní formy N-6 Dasatinibu |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
ES2841248T3 (es) | 2014-02-21 | 2021-07-07 | Principia Biopharma Inc | Sales y forma sólida de un inhibidor de BTK |
CA2882438A1 (en) | 2014-03-11 | 2015-09-11 | Cerbios-Pharma Sa | Process and intermediates for the preparation of dasatinib |
HU231013B1 (hu) | 2014-05-26 | 2019-11-28 | Egis Gyógyszergyár Zrt. | Dasatinib sók |
EP3160963A1 (en) | 2014-06-30 | 2017-05-03 | Basf Se | Multicomponent crystals of dasatinib with menthol or vanillin |
CN104119292A (zh) * | 2014-07-23 | 2014-10-29 | 天津市炜杰科技有限公司 | 一种达沙替尼中间体的制备方法 |
CA2959290A1 (en) | 2014-08-26 | 2016-03-03 | Astellas Pharma Inc. | 2-aminothiazole derivative or salt thereof |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
WO2016059220A1 (en) | 2014-10-16 | 2016-04-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tcr-activating agents for use in the treatment of t-all |
GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
BR112017013022A2 (pt) | 2014-12-18 | 2018-02-27 | Principia Biopharma Inc | métodos para tratar uma doença inflamatória e/ou autoimune aguda num mamífero que a necessite onde a terapia de corticosteróides é utilizada como terapia de primeira ou segunda linha e/ou para tratar uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção de primeira ou segunda linha e/ou para eliminar ou reduzir dose terapêutica de corticosteróides utilizado no tratamento de uma doença inflamatória e/ou autoimune num mamífero que a necessite, onde a terapia de corticosteróides é utilizada como terapia de manutenção crônica de primeira ou segunda linha e/ou de tratamento de uma doença autoimune e/ou inflamatória num mamífero que a necessite |
AU2016233568A1 (en) | 2015-03-13 | 2017-10-05 | Forma Therapeutics, Inc. | Alpha-cinnamide compounds and compositions as HDAC8 inhibitors |
CN104788445B (zh) * | 2015-04-10 | 2017-06-23 | 山东新时代药业有限公司 | 一种达沙替尼中间体的合成方法 |
CN104974222B (zh) * | 2015-06-14 | 2020-06-02 | 深圳市康尔诺生物技术有限公司 | 作为蛋白酪氨酸激酶抑制剂的偶联肽化合物 |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
CN106749223B (zh) * | 2015-11-25 | 2019-12-20 | 中国科学院广州生物医药与健康研究院 | 酪氨酸激酶抑制剂及其制备方法和用途 |
CN106866684B (zh) * | 2015-12-10 | 2020-06-09 | 吴耀东 | 用于治疗肿瘤的大环衍生物 |
WO2017108605A1 (en) | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous dasatinib |
TWI620748B (zh) * | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
WO2017168454A2 (en) * | 2016-04-02 | 2017-10-05 | Sun Pharma Advanced Research Company Limited | Novel compounds as btk inhibitors |
RU2020140891A (ru) | 2016-05-31 | 2021-02-10 | Калвиста Фармасьютикалз Лимитед | Производные пиразола в качестве ингибиторов калликреина |
GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
JP7129704B2 (ja) | 2016-06-29 | 2022-09-02 | プリンシピア バイオファーマ インコーポレイテッド | 2-[3-[4-アミノ-3-(2-フルオロ-4-フェノキシ-フェニル)ピラゾロ[3,4-d]ピリミジン-1-イル]ピペリジン-1-カルボニル]-4-メチル-4-[4-(オキセタン-3-イル)ピペラジン-1-イル]ペント-2-エネニトリルの放出調節製剤 |
WO2018002958A1 (en) | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
RU2019100559A (ru) | 2016-07-14 | 2020-07-14 | Пфайзер Инк. | Новые пиримидиновые карбоксамиды в качестве ингибиторов фермента ванин-1 |
WO2018078392A1 (en) | 2016-10-29 | 2018-05-03 | Cipla Limited | Polymorphs of dasatinib |
US10800771B2 (en) | 2016-12-01 | 2020-10-13 | Natco Pharma Limited | Process for the preparation of dasatinib polymorph |
JP7077335B2 (ja) | 2016-12-13 | 2022-05-30 | プリンストン ドラッグ ディスカバリー インコーポレイテッド | プロテインキナーゼ阻害剤 |
CN106674150A (zh) * | 2016-12-28 | 2017-05-17 | 上海应用技术大学 | 具有抗肿瘤活性的达沙替尼衍生物及其应用 |
IT201700006157A1 (it) | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristalli di un composto antitumorale |
IT201700006145A1 (it) | 2017-01-20 | 2018-07-20 | Cerbios Pharma Sa | Co-cristallo di un composto antitumorale |
EP4233859A1 (en) * | 2017-03-29 | 2023-08-30 | Purdue Research Foundation | Inhibitors of kinase networks and uses thereof |
EP3388430A1 (en) | 2017-04-10 | 2018-10-17 | Technische Universität München | Compound, compound for use in the treatment of a pathological condition, a pharmaceutical composition and a method for preparing said compound |
DK3391907T3 (da) | 2017-04-20 | 2020-03-09 | Iomx Therapeutics Ag | Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf |
EP3649126A4 (en) | 2017-07-07 | 2021-04-07 | Biocon Limited | POLYMORPHIC SHAPES OF DASATINIB |
RU2674443C1 (ru) * | 2017-11-16 | 2018-12-10 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ ингибирования нуклеарного фактора каппа В с использованием 5-гидрокисиникотинат 3-(2,2,2-триметилгидразиний) пропионата калия в культуре клеток |
SI3716952T1 (sl) | 2017-11-29 | 2022-04-29 | Kalvista Pharmaceuticals Limited | Farmacevtske oblike, ki obsegajo zaviralec plazemskega kalikreina |
GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
WO2019169135A1 (en) | 2018-02-28 | 2019-09-06 | University Of Southern California | Compositions and methods for modulating inflammatory and degenerative disorder |
WO2019238886A1 (en) * | 2018-06-13 | 2019-12-19 | University Of Dundee | Bifunctional molecules for targeting usp14 |
JP2021533181A (ja) * | 2018-06-13 | 2021-12-02 | アンフィスタ セラピューティクス リミテッド | UchL5を標的化するための二機能性分子 |
JP2021527137A (ja) * | 2018-06-13 | 2021-10-11 | アンフィスタ セラピューティクス リミテッド | Rpn11を標的化するための二機能性分子 |
CN113321647A (zh) | 2018-06-15 | 2021-08-31 | 汉达癌症医药责任有限公司 | 激酶抑制剂的盐类及其组合物 |
CN108929273A (zh) * | 2018-06-27 | 2018-12-04 | 合肥医工医药有限公司 | 一种咪唑乙基香草酸醚钠盐的制备方法 |
WO2020092650A1 (en) * | 2018-10-30 | 2020-05-07 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating t cell exhaustion |
JPWO2020130125A1 (ja) | 2018-12-21 | 2021-11-04 | 第一三共株式会社 | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ |
CN109438437B (zh) * | 2018-12-24 | 2020-07-17 | 深圳市第二人民医院 | 一类含噻唑环的抗癌化合物 |
KR20230031981A (ko) | 2019-05-14 | 2023-03-07 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
TW202118755A (zh) * | 2019-07-29 | 2021-05-16 | 大陸商蘇州亞盛藥業有限公司 | 作為bcr-abl抑制劑的新型三環化合物 |
CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
CN112409349A (zh) * | 2019-08-20 | 2021-02-26 | 湖南华纳大药厂股份有限公司 | 激酶抑制剂及其制备、药物组合物和用途 |
CN112402422A (zh) * | 2019-08-20 | 2021-02-26 | 湖南华纳大药厂股份有限公司 | 氟取代的2-氨基噻唑-5-芳香族甲酰胺的用途 |
GB201913122D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913123D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913121D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
GB201913124D0 (en) | 2019-09-11 | 2019-10-23 | Seald As | Compositions and methods for treatment of cholangiocarcinoma |
AU2021210974A1 (en) | 2020-01-24 | 2022-09-22 | Nanocopoeia, Llc | Amorphous solid dispersions of dasatinib and uses thereof |
WO2021228983A1 (en) | 2020-05-13 | 2021-11-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer |
KR20220054066A (ko) * | 2020-10-23 | 2022-05-02 | (주)메디톡스 | 단백질 키나제 저해제 및 그의 용도 |
WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
KR20230149753A (ko) * | 2022-04-20 | 2023-10-27 | (주)메디톡스 | 단백질 키나제 저해제 및 그의 용도 |
WO2023215825A1 (en) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Methods for improving t cell efficacy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0275312A1 (en) * | 1986-08-04 | 1988-07-27 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3709992A (en) | 1966-12-07 | 1973-01-09 | Us Rubber Co | Fungicidal use of certain carboxamidothiazoles |
US3725427A (en) | 1966-12-07 | 1973-04-03 | Uniroyal Ltd | Certain 2,4-dimethyl-5-carboxamido-thiazoles |
US3505055A (en) * | 1966-12-07 | 1970-04-07 | Uniroyal Inc | Method of controlling plant growth with carboxamidothiazoles |
DE2128699A1 (de) | 1971-06-09 | 1973-01-25 | Bayer Ag | Thiazylharnstoffe, verfahren zu ihrer herstellung und ihre fungizide verwendung |
US3896223A (en) | 1971-11-22 | 1975-07-22 | Uniroyal Inc | Anti-inflammatory thiazole compositions and methods for using same |
US3796800A (en) * | 1971-11-22 | 1974-03-12 | Uniroyal Inc | Anti-inflammatory triazole compositions and methods for using same |
US3879531A (en) | 1972-07-17 | 1975-04-22 | Uniroyal Inc | 2-aminothiazoles compositions and methods for using them as psychotherapeutic agents |
US3932633A (en) | 1972-12-04 | 1976-01-13 | Uniroyal Inc. | Novel o-triazenobenzamides, in treating aggressive behavior |
JPS57183768A (en) | 1981-05-06 | 1982-11-12 | Kanto Ishi Pharma Co Ltd | 4-methyl-5-(o-carboxyphenyl)carbamoylthiazole derivative and its preparation |
DE3205638A1 (de) | 1982-02-17 | 1983-08-25 | Hoechst Ag, 6230 Frankfurt | Trisubstituierte pyrimidin-5-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel |
DE3220118A1 (de) * | 1982-05-28 | 1983-12-01 | Bayer Ag, 5090 Leverkusen | Alkylenverbrueckte guanidinothiazolderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
US4649146A (en) | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
US4727073A (en) | 1984-10-01 | 1988-02-23 | Fujisawa Pharmaceutical Co., Ltd. | Pyrimidine derivatives and composition of the same |
JPS62123180A (ja) * | 1985-11-21 | 1987-06-04 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
US4837242A (en) * | 1987-01-20 | 1989-06-06 | Sumitomo Chemical Company, Limited | Thiazoles and pyrazoles as fungicides |
JP2552494B2 (ja) | 1987-04-08 | 1996-11-13 | ヘキストジャパン株式会社 | イミダゾチアジアジン誘導体及びその製造法 |
GB8717068D0 (en) * | 1987-07-20 | 1987-08-26 | Fujisawa Pharmaceutical Co | Nitric ester derivative |
US4877441A (en) * | 1987-11-06 | 1989-10-31 | Sumitomo Chemical Company Ltd. | Fungicidal substituted carboxylic acid derivatives |
HU202728B (en) | 1988-01-14 | 1991-04-29 | Eszakmagyar Vegyimuevek | Synergetic fungicide and acaricide compositions containing two or three active components |
US4970318A (en) * | 1988-05-24 | 1990-11-13 | Pfizer Inc. | Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents |
JPH02129171A (ja) | 1988-11-08 | 1990-05-17 | Nissan Chem Ind Ltd | ピラゾールカルボキサニリド誘導体及び有害生物防除剤 |
JPH02275857A (ja) | 1989-01-13 | 1990-11-09 | Yoshitomi Pharmaceut Ind Ltd | ピリジン誘導体 |
US5539122A (en) | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
US5064825A (en) | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
KR0163595B1 (ko) | 1989-06-30 | 1998-12-01 | 미리암디, 메코너헤이 | 치환된 이미다졸 |
TW205041B (ko) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
DE3934197A1 (de) | 1989-10-13 | 1991-04-18 | Bayer Ag | Thiazolcarbonsaeureamid-derivate |
JPH04316559A (ja) | 1990-11-28 | 1992-11-06 | Nissan Chem Ind Ltd | ピラゾールカルボキサニリド誘導体及び殺菌剤 |
AU664392B2 (en) | 1991-10-18 | 1995-11-16 | Monsanto Technology Llc | Fungicides for the control of take-all disease of plants |
DE4138042C2 (de) | 1991-11-19 | 1993-10-14 | Biotechnolog Forschung Gmbh | Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel |
JPH05345780A (ja) | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
HUT63941A (en) | 1992-05-15 | 1993-11-29 | Hoechst Ag | Process for producing 4-alkyl-substituted pyrimidine-5-carboxanilide derivatives, and fungicidal compositions comprising same |
IL105939A0 (en) | 1992-06-11 | 1993-10-20 | Rhone Poulenc Agriculture | Herbicidal compounds and compositions |
DE4231517A1 (de) | 1992-09-21 | 1994-03-24 | Basf Ag | Carbonsäureanilide, Verfahren zu ihrer Herstellung und sie enthaltende Mittel zur Bekämpfung von Schadpilzen |
HRP921338B1 (en) | 1992-10-02 | 2002-04-30 | Monsanto Co | Fungicides for the control of take-all disease of plants |
EP0603595A1 (de) | 1992-12-04 | 1994-06-29 | Hoechst Aktiengesellschaft | Faserreaktive Farbstoffe, Verfahren zu deren Herstellung und ihre Verwendung |
CA2158737A1 (en) | 1993-04-07 | 1994-10-13 | Keizo Tanikawa | Pyrazole derivatives |
US5514643A (en) * | 1993-08-16 | 1996-05-07 | Lucky Ltd. | 2-aminothiazolecarboxamide derivatives, processes for preparing the same and use thereof for controlling phytopathogenic organisms |
WO1995018116A1 (en) | 1993-12-29 | 1995-07-06 | E.I. Du Pont De Nemours And Company | Arthropodicidal oxadiazine-, thiadiazine- or triazine-carboxanilides |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
US5582167A (en) * | 1994-03-02 | 1996-12-10 | Thomas Jefferson University | Methods and apparatus for reducing tracheal infection using subglottic irrigation, drainage and servoregulation of endotracheal tube cuff pressure |
WO1996000218A1 (en) | 1994-06-24 | 1996-01-04 | Euro-Celtique, S.A. | Compounds for and method of inhibiting phosphodiesterase iv |
US5922751A (en) | 1994-06-24 | 1999-07-13 | Euro-Celtique, S.A. | Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same |
US6080772A (en) * | 1995-06-07 | 2000-06-27 | Sugen, Inc. | Thiazole compounds and methods of modulating signal transduction |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
CA2230894A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
ATE218556T1 (de) | 1995-11-17 | 2002-06-15 | Biotechnolog Forschung Gmbh | Epothilon-derivate und deren herstellung |
US5677097A (en) | 1996-01-18 | 1997-10-14 | Fuji Xerox Co., Ltd. | Electrophotographic photoreceptor |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
WO1997036875A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
DK1367057T3 (da) | 1996-11-18 | 2009-01-19 | Biotechnolog Forschung Gmbh | Epothiloner E og F |
CA2273083C (en) | 1996-12-03 | 2012-09-18 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6380394B1 (en) | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
US6187797B1 (en) * | 1996-12-23 | 2001-02-13 | Dupont Pharmaceuticals Company | Phenyl-isoxazoles as factor XA Inhibitors |
EP0946528B1 (en) * | 1996-12-23 | 2003-04-09 | Bristol-Myers Squibb Pharma Company | OXYGEN OR SULFUR CONTAINING 5-MEMBERED HETEROAROMATICS AS FACTOR Xa INHIBITORS |
KR100494179B1 (ko) | 1997-02-25 | 2005-06-10 | 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) | 변환된 측쇄를 가진 에포틸론 |
AU7687998A (en) | 1997-05-19 | 1998-12-11 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
GB9801231D0 (en) | 1997-06-05 | 1998-03-18 | Merck & Co Inc | A method of treating cancer |
US5896223A (en) * | 1997-06-13 | 1999-04-20 | Tigliev; George S. | Optical system having an unlimited depth of focus |
WO1998056376A1 (en) * | 1997-06-13 | 1998-12-17 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction |
PT991625E (pt) * | 1997-06-19 | 2005-10-31 | Bristol Myers Squibb Pharma Co | Inibidores de factor xa com um grupo de especificidade p1 neutro |
US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
WO1999002224A1 (en) | 1997-07-07 | 1999-01-21 | Lewis Robert D | Statistical analysis and feedback system for sports employing a projectile |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
JPH1180137A (ja) | 1997-07-10 | 1999-03-26 | Nissan Chem Ind Ltd | カルバモイルテトラゾールおよび除草剤 |
US6384230B1 (en) | 1997-07-16 | 2002-05-07 | Schering Aktiengesellschaft | Thiazole derivatives, method for their production and use |
DK1005465T3 (da) | 1997-08-09 | 2007-11-05 | Bayer Schering Pharma Ag | Nye epothilon-derivater, fremgangsmåde til fremstilling heraf og deres farmaceutiske anvendelse |
ID24372A (id) * | 1997-10-27 | 2000-07-13 | Agouron Pharma | SENYAWA-SENYAWA 4-AMINO-TIAZOL-2-IL SEBAGAI PENGHAMBAT-PENGHAMBAT CDKs |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
KR20010031912A (ko) * | 1997-11-10 | 2001-04-16 | 스티븐 비. 데이비스 | 벤조티아졸 단백질 티로신 키나제 억제제 |
US6040321A (en) | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
EP1042327B1 (en) | 1997-12-04 | 2003-09-17 | Bristol-Myers Squibb Company | A process for the reduction of oxiranyl epothilones to olefinic epothilones |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
ES2308821T3 (es) | 1997-12-15 | 2008-12-01 | Astellas Pharma Inc. | Nuevos derivados de pirimidin-5-carboxamida. |
JPH11180965A (ja) | 1997-12-24 | 1999-07-06 | Nissan Chem Ind Ltd | 新規カルバモイルテトラゾリノンおよび除草剤 |
EP0928790B1 (en) * | 1998-01-02 | 2003-03-05 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
SI0928793T1 (en) | 1998-01-02 | 2002-10-31 | F. Hoffmann-La Roche Ag | Thiazole derivatives |
MXPA00008365A (es) | 1998-02-25 | 2002-11-07 | Sloan Kettering Inst Cancer | Sintesis de epotilonas, intermediarios y analogos de las mismas. |
WO1999047529A1 (en) | 1998-03-18 | 1999-09-23 | Ariad Pharmaceuticals, Inc. | Heterocyclic signal transduction inhibitors, compositions containing them |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
HUP0101581A3 (en) | 1998-05-05 | 2002-07-29 | Hoffmann La Roche | Pyrazole derivatives as p-38 map kinase inhibitors, the pharmaceutical compositions containing the same, process for their preparation and their use |
MY132496A (en) | 1998-05-11 | 2007-10-31 | Vertex Pharma | Inhibitors of p38 |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
DE19826988A1 (de) | 1998-06-18 | 1999-12-23 | Biotechnolog Forschung Gmbh | Epothilon-Nebenkomponenten |
WO1999067253A2 (en) | 1998-06-22 | 1999-12-29 | Novartis Ag | Desmethyl epothilones |
AU5036999A (en) | 1998-06-30 | 2000-01-17 | Schering Aktiengesellschaft | Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use |
JP2002520324A (ja) | 1998-07-10 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | 新規な血管形成インヒビター |
GB2323595A (en) | 1998-07-29 | 1998-09-30 | Zeneca Ltd | Preparation of 2-Mercaptothiazole |
WO2000017175A1 (en) | 1998-09-18 | 2000-03-30 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
JP3244672B2 (ja) | 1998-10-13 | 2002-01-07 | 住友製薬株式会社 | イソキサゾール誘導体からなる医薬 |
CZ20011395A3 (cs) * | 1998-10-22 | 2001-08-15 | F. Hoffmann-La Roche Ag | Deriváty thiazolu |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
GB9823873D0 (en) | 1998-10-30 | 1998-12-30 | Pharmacia & Upjohn Spa | 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
AU765492B2 (en) | 1998-12-25 | 2003-09-18 | Teikoku Hormone Mfg. Co., Ltd. | Aminopyrazole derivatives |
AU2460600A (en) | 1999-02-10 | 2000-08-29 | Mitsubishi Pharma Corporation | Amide compounds and medicinal use thereof |
KR100342044B1 (ko) | 1999-04-14 | 2002-06-27 | 김순택 | 녹색발광 형광체 조성물 및 이를 이용하여 제조된 음극선관 |
BRPI0009721B1 (pt) * | 1999-04-15 | 2018-11-21 | Bristol-Myers Squibb Holdings Ireland | inibidores de tirosina quinase de proteína cíclica |
US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
CA2381215A1 (en) | 1999-08-06 | 2001-02-15 | Takeda Chemical Industries, Ltd. | P38map kinase inhibitors |
JP2003531103A (ja) | 1999-08-12 | 2003-10-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | c−JUNN−末端キナーゼ(JNK)および他のタンパク質キナーゼの阻害剤 |
US6114365A (en) | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
ATE309241T1 (de) | 1999-09-10 | 2005-11-15 | Merck & Co Inc | Tyrosin kinase inhibitoren |
ES2287096T3 (es) * | 2000-01-19 | 2007-12-16 | Synvista Therapeutics, Inc. | Compuestos de tiazol, imidazol y oxazol y tratamientos de trastornos asociados con el envejecimiento de las proteinas. |
WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
EP1578341A2 (en) * | 2000-10-11 | 2005-09-28 | Tularik Inc. | Modulation of ccr4 function |
US20020132836A1 (en) * | 2000-10-11 | 2002-09-19 | Chemocentryx Inc. | Compounds and methods for modulating CCR4 function |
US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
EP1353676A4 (en) * | 2000-12-29 | 2006-05-31 | Alteon Inc | METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS |
JP2002338537A (ja) | 2001-05-16 | 2002-11-27 | Mitsubishi Pharma Corp | アミド化合物およびその医薬用途 |
WO2002094798A1 (fr) | 2001-05-23 | 2002-11-28 | Nippon Soda Co.,Ltd. | Preparation de composes thiazole |
US7144903B2 (en) * | 2001-05-23 | 2006-12-05 | Amgen Inc. | CCR4 antagonists |
JP4011359B2 (ja) | 2002-02-15 | 2007-11-21 | 株式会社ニフコ | カップホルダ装置 |
US20050009891A1 (en) | 2003-07-09 | 2005-01-13 | Lee Francis Y. | Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
US7652146B2 (en) * | 2004-02-06 | 2010-01-26 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors |
US7491725B2 (en) | 2004-02-06 | 2009-02-17 | Bristol-Myers Squibb Company | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
TW200628156A (en) * | 2004-11-04 | 2006-08-16 | Bristol Myers Squibb Co | Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases |
US20060235006A1 (en) * | 2005-04-13 | 2006-10-19 | Lee Francis Y | Combinations, methods and compositions for treating cancer |
SI1885339T1 (sl) * | 2005-05-05 | 2015-10-30 | Bristol-Myers Squibb Holdings Ireland | Formulacije inhibitorja src/abl |
WO2007035874A1 (en) * | 2005-09-21 | 2007-03-29 | Bristol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
JP4316559B2 (ja) | 2005-11-30 | 2009-08-19 | 株式会社ナノクリエート | 導光板及びその製造方法 |
US8554512B2 (en) | 2006-06-13 | 2013-10-08 | Nike, Inc. | Athletic performance data system and method |
US7678998B2 (en) | 2007-05-21 | 2010-03-16 | Cicoil, Llc | Cable assembly |
US8897586B2 (en) | 2012-06-15 | 2014-11-25 | Comcast Cable Communications, Llc | Dynamic generation of a quantization matrix for compression of a digital object |
-
2000
- 2000-04-12 BR BRPI0009721A patent/BRPI0009721B1/pt unknown
- 2000-04-12 WO PCT/US2000/009753 patent/WO2000062778A1/en not_active Application Discontinuation
- 2000-04-12 EP EP00922102.9A patent/EP1169038B9/en not_active Revoked
- 2000-04-12 TR TR2001/02969T patent/TR200102969T2/xx unknown
- 2000-04-12 ID IDW00200102219A patent/ID30460A/id unknown
- 2000-04-12 CA CA002366932A patent/CA2366932C/en not_active Expired - Lifetime
- 2000-04-12 JP JP2000611914A patent/JP3989175B2/ja not_active Expired - Lifetime
- 2000-04-12 IL IL14491000A patent/IL144910A0/xx active IP Right Grant
- 2000-04-12 EP EP10013204A patent/EP2308833A3/en not_active Ceased
- 2000-04-12 PT PT00922102T patent/PT1169038E/pt unknown
- 2000-04-12 CZ CZ20013677A patent/CZ302788B6/cs not_active IP Right Cessation
- 2000-04-12 NZ NZ513639A patent/NZ513639A/xx not_active IP Right Cessation
- 2000-04-12 MX MXPA01010292A patent/MXPA01010292A/es active IP Right Grant
- 2000-04-12 CN CN00806206A patent/CN1348370A/zh active Pending
- 2000-04-12 AU AU42338/00A patent/AU779089B2/en not_active Expired
- 2000-04-12 DK DK00922102.9T patent/DK1169038T3/da active
- 2000-04-12 KR KR1020077002337A patent/KR100722344B1/ko active IP Right Review Request
- 2000-04-12 CN CNA2008101817940A patent/CN101481359A/zh active Pending
- 2000-04-12 HU HU0202708A patent/HUP0202708A3/hu not_active Application Discontinuation
- 2000-04-12 PL PL351126A patent/PL215901B1/pl unknown
- 2000-04-12 RU RU2001130452A patent/RU2260592C9/ru active Protection Beyond IP Right Term
- 2000-04-12 EP EP17167936.8A patent/EP3222619A1/en not_active Ceased
- 2000-04-12 RU RU2005107463/04A patent/RU2312860C2/ru active
- 2000-04-12 BR BR0009721-7A patent/BR0009721A/pt active IP Right Grant
- 2000-04-12 ES ES00922102T patent/ES2391550T3/es not_active Expired - Lifetime
- 2000-04-12 KR KR1020017013067A patent/KR100710100B1/ko not_active IP Right Cessation
- 2000-04-13 US US09/548,929 patent/US6596746B1/en not_active Expired - Lifetime
-
2001
- 2001-08-15 IL IL144910A patent/IL144910A/en not_active IP Right Cessation
- 2001-08-30 ZA ZA200107204A patent/ZA200107204B/en unknown
- 2001-10-12 NO NO20014970A patent/NO322470B1/no not_active IP Right Cessation
-
2002
- 2002-05-10 HK HK02103550.4A patent/HK1042433B/zh unknown
-
2003
- 2003-03-03 US US10/378,373 patent/US20040077875A1/en not_active Abandoned
- 2003-03-03 US US10/378,372 patent/US6979694B2/en not_active Expired - Lifetime
- 2003-03-03 US US10/378,461 patent/US7091223B2/en not_active Expired - Lifetime
-
2005
- 2005-05-25 US US11/138,793 patent/US7189854B2/en not_active Expired - Lifetime
- 2005-05-26 US US11/138,942 patent/US7153856B2/en not_active Expired - Lifetime
- 2005-11-10 US US11/271,626 patent/US8716323B2/en not_active Expired - Fee Related
-
2007
- 2007-03-27 NO NO2007005C patent/NO2007005I1/no not_active IP Right Cessation
-
2012
- 2012-11-06 CY CY20121101056T patent/CY1113312T1/el unknown
-
2013
- 2013-01-11 FR FR13C0003C patent/FR13C0003I2/fr active Active
- 2013-01-14 CY CY2013005C patent/CY2013005I2/el unknown
- 2013-02-05 LU LU92146C patent/LU92146I2/fr unknown
-
2014
- 2014-03-27 US US14/226,868 patent/US8993567B2/en not_active Expired - Fee Related
-
2015
- 2015-02-12 US US14/620,244 patent/US9382219B2/en not_active Expired - Lifetime
-
2016
- 2016-05-25 US US15/163,750 patent/US20160264537A1/en not_active Abandoned
-
2017
- 2017-09-27 US US15/716,905 patent/US20180016247A1/en not_active Abandoned
-
2018
- 2018-03-26 HK HK18104141.0A patent/HK1244797A1/zh unknown
-
2019
- 2019-03-18 US US16/355,887 patent/US20190210986A1/en not_active Abandoned
- 2019-04-05 NO NO2019016C patent/NO2019016I1/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0275312A1 (en) * | 1986-08-04 | 1988-07-27 | Otsuka Pharmaceutical Factory, Inc. | Thiazole derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100722344B1 (ko) | 환형 단백질 티로신 키나제 억제제 | |
KR101070101B1 (ko) | 환형 단백질 티로신 키나제 억제제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130502 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140502 Year of fee payment: 8 |
|
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20150416 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160419 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170420 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180417 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190417 Year of fee payment: 13 |